Major review clears pregnancy Tylenol of autism and ADHD risks

A comprehensive scientific review has concluded that taking acetaminophen, known as Tylenol, during pregnancy does not increase the risk of autism, ADHD, or intellectual disability in children. Led by researchers at City St George's, University of London, the study analyzed 43 high-quality studies, including sibling comparisons to isolate medication effects from genetic and environmental factors. The findings, published on January 16, 2026, in The Lancet Obstetrics, Gynaecology & Women's Health, address earlier concerns sparked by less robust research.

The review, a systematic analysis and meta-analysis, examined data from over 1 million children across various studies. Specifically, it assessed outcomes for 262,852 children for autism, 335,255 for ADHD, and 406,681 for intellectual disability. Using sibling comparisons—where one child was exposed to acetaminophen in utero and another was not—the researchers found no elevated risks compared to unexposed pregnancies. This method helps control for shared genetics and family environments that could confound results.

Public concern had grown following claims in September 2025 linking prenatal acetaminophen to brain development issues and higher autism rates. However, prior studies often suffered from limitations like incomplete data or failure to account for family history. The new analysis prioritized high-quality evidence, evaluating studies with the Quality In Prognosis Studies (QUIPS) tool to minimize bias. Results held firm even in low-bias studies tracking children beyond five years.

Professor Asma Khalil, who led the study as Professor of Obstetrics and Maternal Fetal Medicine at City St George's, University of London, explained the implications. "Our findings suggest that previously reported links are likely to be explained by genetic predisposition or other maternal factors such as fever or underlying pain, rather than a direct effect of the paracetamol itself," she said. She added, "The message is clear—paracetamol remains a safe option during pregnancy when taken as guided. This is important as paracetamol is the first-line medication we recommend for pregnant women in pain or with a fever, and so they should feel reassured that they still have a safe option to relieve them of their symptoms."

While the review aligns with global medical guidelines, it noted gaps in data on exposure by trimester, child sex, or dosage frequency due to insufficient reporting in sibling studies. Untreated pain or fever during pregnancy poses its own risks, reinforcing the value of acetaminophen as a first-line treatment when used properly.

Verwandte Artikel

Photorealistic depiction of a premature baby in NICU amid warnings of rising cases from maternal drug use.
Bild generiert von KI

Anzahl schwangerer Drogennutzerinnen und Frühgeborener steigt

Von KI berichtet Bild generiert von KI

Es gibt keine offiziellen Zahlen, aber Fachkräfte, die Mütter und Neugeborene betreuen, warnen vor einem Anstieg von Frühgeburtenfällen durch Konsum psychoaktiver Substanzen während der Schwangerschaft.

Das kolumbianische Ministerium für Gesundheit und Sozialschutz hat vor den Risiken eines übermäßigen Paracetamol-Konsums bei Minderjährigen gewarnt, der als „Paracetamol-Challenge“ bekannt ist. Diese durch soziale Medien beeinflusste Praxis führt zu Überdosierungen sowie zu schweren Leber- und Nierenschäden.

Von KI berichtet

New research challenges long-standing concerns about the antiviral drug oseltamivir, known as Tamiflu, and its potential link to serious neuropsychiatric events in children. Instead, the study attributes such symptoms to the influenza virus itself and shows that Tamiflu treatment halves the risk of these complications. The findings, based on a large analysis of pediatric health records, aim to reassure families and doctors about the drug's safety.

A major review published in The Lancet Psychiatry concludes that medicinal cannabis does not effectively treat anxiety, depression or post-traumatic stress disorder. The analysis of 54 randomized controlled trials over 45 years found limited evidence for other conditions like insomnia and autism. Researchers warn of potential harms including psychosis risk and delayed effective treatments.

Von KI berichtet

A comprehensive analysis of over 2,500 studies shows that medical cannabis has strong evidence for only a few specific uses, despite widespread public belief in its broader effectiveness. Led by UCLA Health researchers, the review highlights gaps between perceptions and scientific proof for conditions like chronic pain and anxiety. It also identifies potential risks, particularly for adolescents and daily users.

Researchers in Taiwan report that a low-dose combination of zinc, serine, and branched-chain amino acids improves neural function and social behaviors across several mouse models of autism spectrum disorder. The nutrient mix, which appears to act synergistically, restores more typical synaptic protein patterns and reduces excessive activity in the amygdala, according to a study in PLOS Biology.

Von KI berichtet

A new study in Gastroenterology connects early life stress to long-term gut issues through disruptions in gut-brain communication. Mouse experiments and large human cohorts show links to pain, constipation, and irritable bowel syndrome. Researchers suggest targeted treatments based on specific biological pathways.

 

 

 

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen